[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pontine-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pontine-tumors":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100523249","re-irradiation-of-diffuse-midline-glioma-patients-100523249",false,"NCT06093165","RE-irradiation of Diffuse MIdline Glioma paTients","REMIT","Inclusion Criteria:\n\n* Diffuse midline glioma diagnosis: verified radiologically or histologically Biopsy is not mandatory for REMIT\n* Age ≥ 12 months to ≤21 years.\n* Min. 180 days\u002F6 months have elapsed from the first day of the 1st RT course\n* 1st course of radiotherapy\n* Full recovery from all acute and subacute toxicities of 1st RT course\n* Clinical progression of symptoms and\u002For radiographic progression\n* Karnofsky performance status scale or Lansky Play Scale \\> 50% The performance status should not take the neurological deficits per se into account.\n\nNB: Children and adults with a worsening performance status due to glioma-related motor deficit can be included.\n\n* Life expectancy \\> 12 weeks after start of reRT\n* Signed informed consent by patient and\u002For parents or legal guardian\n\nExclusion Criteria:\n\n* Presence of leptomeningeal spread or multifocal disease on MRI at progression\n* Other co-morbidity that according to the treating physician would impair participation in the study\n* \\>1 course of radiotherapy\n* Neurofibromatosis type 1\n* Inability to complete the medical follow-up (geographic, social, or mental reasons)","ALL","12 Months","21 Years",{"count":20,"type":21},59,"ESTIMATED","INTERVENTIONAL",[24],"NA","The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.",[27,28,29,30,31,32],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma","Diffuse Glioma","Pontine Tumors","Thalamic Tumor","Brain Tumor, Pediatric","NOT_YET_RECRUITING","2023-10-16",{"date":36,"type":37},"2023-10-23","ACTUAL",{"date":39,"type":21},"2023-10",{"date":41,"type":21},"2029-11",{"name":43,"class":44},"Rigshospitalet, Denmark","OTHER"]